Vanucizumab, referred to as VPC-600, represents a novel therapeutic antibody specifically intended for vascular endothelial growth factor A . This selective agent works by connecting to VEGF-A, substantially inhibiting its attachment with its binding sites and subsequently lessening angiogenesis—